陸明 男 北京腫瘤醫(yī)院消化腫瘤內(nèi)科的主任醫(yī)師、副教授、碩士生指導(dǎo)老師，2009年畢業(yè)于北京大學(xué)臨床腫瘤學(xué)院，獲腫瘤學(xué)博士學(xué)位，從事腫瘤臨床工作近20年。擅長消化系統(tǒng)腫瘤包括神經(jīng)內(nèi)分泌腫瘤、胃癌、食管癌、腸癌、胰腺癌、等病種的個體化和多學(xué)科綜合治療，具有豐富的臨床經(jīng)驗。熟悉各領(lǐng)域的國際最新進展，研究方向主要專注于神經(jīng)內(nèi)分泌腫瘤的分子分型、個體化多學(xué)科治療和轉(zhuǎn)化治療等。參與幾十項國內(nèi)國際臨床研究的病例入組和診治管理工作。以第一/通訊作者在Clinical cancer research、Cancer、Cancer communications、Cancer science、Oncotarget、Medicine等雜志發(fā)表相關(guān)論文十余篇。主持國家級和省部級基金課題2項。獲中國抗癌協(xié)會科技一等獎、北京大學(xué)首屆臨床醫(yī)療獎等。

社會兼職：中國臨床腫瘤學(xué)會(CSCO)神經(jīng)內(nèi)分泌腫瘤委員會委員;中國醫(yī)療保健國際交流促進會神經(jīng)內(nèi)分泌腫瘤分會委員;中國醫(yī)學(xué)前沿雜志(電子版)編輯委員會編輯部部主任。

代表性論文、專著及專利情況

1. Ming Lu, Panpan Zhang (joint first author), Lin Shen, et al, Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial. (Clinical Caner Research. IF 10.199);

2. Panpan Zhang, Jie Li, Lin Shen, Ming Lu, et al. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for advanced poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: a randomized phase II study. (Cancer. IF 6.102)

3. Yansuo Cao, Yutong Ma, Jiangyuan Yu……Ming Lu. Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden. Cancer Communications. 2020;1–6.

4. Li Jie Lu M, ZH Lu et al. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma：IPO-NEC Study. Oncotarget.2016.

5. Panpan Zhang Jiangyuan Yu,Jie Li, Lin Shen , Nan Li, Hua Zhu, Shizhen Zhai,Yan Zhang, Zhi Yang, and Ming Lu. Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms. Contrast Media & Molecular Imaging. 2018 Feb 26;2018:2340389.

6. Lu M, Wang X, Shen L et al. Nimotuzumab Plus Paclitaxel and Cisplatin as the 1st Line Treatment for Advanced Esophageal Squamous Cell Cancer (ESCC): a Single Centre Prospective Phase II Trial. Cancer Sci. 2016 Apr;107(4):486-90.

7. Lu, Ming; Yang, Zuyao; Feng, Qi et al. The characteristics and prognostic value of signet ring cell histology in gastric cancer: A retrospective cohort study of 2199 consecutive patients. Medicine, 2016, 95(27): e4052

8. 劉丹, 陸明.胃神經(jīng)內(nèi)分泌腫瘤的診斷和治療. 臨床腫瘤學(xué)雜志. 2015;20(6):549-554

9. 陸明.胃腸道神經(jīng)內(nèi)分泌癌(WHO G3)的異質(zhì)性和個體化治療. 中國醫(yī)學(xué)前沿雜志(電子版). 2014;6(11):16-19

10. 陸明,沈琳.晚期胰腺神經(jīng)內(nèi)分泌腫瘤的綜合治療. 中國實用外科雜志. 2014;34(6):19-23